Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: A Liposomal delivery system is a novel and distinguishing way of organized medicine administration. The advancements in liposomal technology allow for controlled drug distribution to treat rheumatoid arthritis effectively. Liposomes are microscopic lipid-based vesicles that have shown promise in transporting substances, such as superoxide dismutase, hemoglobin, erythrocyte interleukin-2, gamma interferon, and smaller compounds.
Objective: Liposomes are biocompatible, nontoxic, biodegradable, non-immunogenic, and flexible, with sizes ranging from 0.025 to 2.5 micrometers. LDS is normally employed to distribute drugs through topical conduits, but fresh investigation has shown that it offers promise for oral, ocular, and parenteral administration. Our major objective is to gather information about liposomes, focusing on their applicability in rheumatoid arthritis treatment.
Methods: In the current review, we have tried to cover the preparation techniques, clinical trials, patents, marketed formulations, vesicle types, formulations used to treat rheumatoid arthritis and other ailments, and layered liposomal formulations with improved characteristics.
Conclusion: Research has established LDS as a biocompatible, sustainable, non-toxic, adaptable material. Researchers working on LDS technology in rheumatoid arthritis will find this review particularly useful as it may unclutter novel ways for therapeutic intercessions in treating the disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0115733971284274240215064826 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural Products for Regulation of Autoimmune Diseases: Chemical Diversity, Pharmacology, and Therapeutic Applications.
Chem Biodivers
September 2025
Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Laboratory of Anti-Allergy Functional Compounds, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Autoimmune diseases (AIDs), defined by irregularities in immune system function, pose a substantial health challenge worldwide, impacting millions with persistent and frequently debilitating conditions. Conventional treatments, such as glucocorticoid-based immunosuppressive therapies, are associated with notable drawbacks and limitations. In response to these difficulties, recent scientific efforts have increasingly focused on natural compounds as potential therapeutic agents.
View Article and Find Full Text PDFComment on: Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from FIRST registry.
Rheumatology (Oxford)
September 2025
Department of Rheumatology, Kochi Memorial Hospital, Kochi, Kochi Prefecture, Japan.
Biaryl Phosphate-Based Inhibitors of the Transcription Factor STAT4.
ChemMedChem
September 2025
Institute of Organic Chemistry, Leipzig University, Johannisallee 29, 04103, Leipzig, Germany.
The transcription factor signal transducer and activator of transcription (STAT)4 is a potential target for autoimmune diseases, such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes mellitus. p-Biphenyl phosphate is reported as an inhibitor of the STAT4 Src homology 2 domain, and it is developed to the phosphonate-based inhibitor Stafori-1. Herein, structure-activity relationships of p-biaryl phosphates against STAT4 and their selectivity profiles against other STAT proteins are reported.
View Article and Find Full Text PDFSynovial MS4A4A correlates with inflammation and counteracts response to corticosteroids in arthritis.
Proc Natl Acad Sci U S A
September 2025
Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, United Kingdom.
MS4A4A belongs to the MS4A tetraspan protein superfamily and is selectively expressed by the monocyte-macrophage lineage. In this study, we aimed to evaluate the role of MS4A4A+ macrophages in rheumatoid arthritis (RA) pathogenesis and response to treatment. RNA sequencing and immunohistochemistry of synovial samples from either early treatment-naïve or active chronic RA patients showed that MS4A4A expression positively correlated with synovial inflammation.
View Article and Find Full Text PDFDigital Psychological Intervention for Inflammatory Rheumatic Diseases: A Pilot Randomized Clinical Trial.
JAMA Netw Open
September 2025
Department of Psychiatry, Psychosomatics, and Psychotherapy, University of Lübeck, Lübeck, Germany.
Importance: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress; however, access to psychological support remains limited.
Objective: To investigate the effectiveness of a digital psychological intervention for individuals with IRDs.
Design, Setting, And Participants: Participants aged 18 years or older were recruited across Germany between February 22 and June 4, 2024, if they had been diagnosed with rheumatoid arthritis, psoriatic arthritis, or systemic lupus erythematosus and reported psychological distress and reduced quality of life.